IGF2BP3 and colorectal carcinoma: In our study, we also added a corresponding rescue experiment to confirm that IGF2BP3 directly targeted EGFR in an m6A-dependent manner to promote CRC progression and drug resistance, which weakened the influence of other factors on the experimental results.